Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population

Suna BÜYÜKÖZTÜRK, Aslı GELINCIK, Mustafa DEMIRTÜRK, Emek KOCATURK, Bahattin ÇOLAKOĞLU, Murat DAL, Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. Journal of Dermatology. ,vol. 39, pp. 439- 442 ,(2012) , 10.1111/J.1346-8138.2011.01473.X

Moises Labrador-Horrillo, Marta Ferrer, Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Design Development and Therapy. ,vol. 9, pp. 4909- 4915 ,(2015) , 10.2147/DDDT.S56004

Sarbjit S. Saini, Carsten Bindslev-Jensen, Marcus Maurer, Jean-Jacques Grob, Emel Bülbül Baskan, Mary S. Bradley, Janice Canvin, Abdelkader Rahmaoui, Panayiotis Georgiou, Oral Alpan, Sheldon Spector, Karin Rosén, Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. Journal of Investigative Dermatology. ,vol. 135, pp. 67- 75 ,(2015) , 10.1038/JID.2014.306

Shira Wieder, Marcus Maurer, Mark Lebwohl, Treatment of Severely Recalcitrant Chronic Spontaneous Urticaria: A Discussion of Relevant Issues American Journal of Clinical Dermatology. ,vol. 16, pp. 19- 26 ,(2015) , 10.1007/S40257-014-0103-7

P.M. Silva, A.C. Costa, A. Mendes, M.P. Barbosa, Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria Allergologia Et Immunopathologia. ,vol. 43, pp. 168- 173 ,(2015) , 10.1016/J.ALLER.2013.11.007

I. Baiardini, M. Pasquali, F. Braido, F. Fumagalli, L. Guerra, E. Compalati, M. Braga, C. Lombardi, O. Fassio, G. W. Canonica, A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU‐Q2oL) Allergy. ,vol. 60, pp. 1073- 1078 ,(2005) , 10.1111/J.1398-9995.2005.00833.X

T Zuberbier, W Aberer, R Asero, C Bindslev‐Jensen, Z Brzoza, GW Canonica, MK Church, LF Ensina, A Giménez‐Arnau, K Godse, M Gonçalo, C Grattan, J Hebert, M Hide, A Kaplan, A Kapp, AH Abdul Latiff, P Mathelier‐Fusade, M Metz, SS Saini, M Sánchez‐Borges, P Schmid‐Grendelmeier, FER Simons, P Staubach, G Sussman, E Toubi, GA Vena, B Wedi, XJ Zhu, A Nast, M Maurer, None, Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. ,vol. 69, ,(2014) , 10.1111/ALL.12370

Martin Metz, Tatevik Ohanyan, Martin K. Church, Marcus Maurer, Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis Journal of Dermatological Science. ,vol. 73, pp. 57- 62 ,(2014) , 10.1016/J.JDERMSCI.2013.08.011

Oliver Kornmann, Henrik Watz, Rainard Fuhr, Norbert Krug, Veit J. Erpenbeck, Guenther Kaiser, Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table Pulmonary Pharmacology & Therapeutics. ,vol. 28, pp. 149- 153 ,(2014) , 10.1016/J.PUPT.2014.03.003

A.Y. FINLAY, G.K. KHAN, Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use Clinical and Experimental Dermatology. ,vol. 19, pp. 210- 216 ,(1994) , 10.1111/J.1365-2230.1994.TB01167.X